Norgine and Jubilant Biosys Ltd., a subsidiary of Jubilant Life Sciences, have entered into a discovery collaboration to provide a platform for Norgine to develop multiple targets using Jubilant’s drug discovery platform targeting gastrointestinal diseases. The initial term of the agreement is three years. Jubilant will deliver preclinical candidates and Norgine will have rights to further development and commercialization.
 
Sri Mosur, president and chief executive officer, Global Drug Discovery and Development at Jubilant, said, “Jubilant is very pleased to partner with Norgine, a very successful European specialty pharmaceutical company. We are confident our ‘accelerated discovery’ platform will enable Norgine’s quest for novel and optimal therapies in delivering affordable care to the unmet needs of patients in Europe and worldwide in the area of gastrointestinal disease.”

Ian Cox, vice president of Pharmaceutical & Preclinical Development at Norgine, commented, “We are delighted to be collaborating with Jubilant, a company with a track record in these types of discovery programs, and we genuinely look forward to a productive and fruitful relationship.”